

Special Issue

Personalized Diagnosis and Treatment of Patients with Sepsis

Message from the Guest Editors

Diagnostics and therapy of sepsis still represent the "Holy Grail" of 21st century medicine. The aim of this Special Issue is to provide information on the current and potential use of personalized medicine in sepsis. Sepsis is a multifactorial clinical syndrome with an extremely dynamic clinical course, and is very diverse with respect to clinical phenotype. Early diagnosis is of crucial importance for the final clinical outcome. Previous studies have not identified a biomarker with sufficient sensitivity and specificity for the diagnosis of sepsis. Identification of the infectious agents or the use of molecular biology, next-gene sequencing has not brought significant benefits for patients in terms of early diagnosis. Therefore, we are currently searching for biomarkers, through "omics" technologies with sufficient diagnostic specificity and sensitivity, that are able to predict the clinical course of the disease, and patient response to therapy. Current progress in the use of systems biology technologies brings us hope that by using big data from clinical trials, such biomarkers will be found.

Guest Editors

Dr. Miroslav Průcha

Prof. Dr. Michael Bauer

Dr. Roman Zahorec

Deadline for manuscript submissions

closed (10 August 2021)



Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



mdpi.com/si/54822

*Journal of Personalized
Medicine*
Editorial Office
MDPI, Grosspeteranlage 5
4052 Basel, Switzerland
Tel: +41 61 683 77 34
jpm@mdpi.com

[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)





Journal of Personalized Medicine

an Open Access Journal
by MDPI

CiteScore 6.0
Indexed in PubMed



[mdpi.com/journal/
jpm](https://mdpi.com/journal/jpm)



About the Journal

Message from the Editor-in-Chief

Journal of Personalized Medicine (JPM), ISSN 2075-4426) is an international, open access journal aimed at bringing all aspects of personalized medicine to one platform. *JPM* publishes cutting edge, innovative preclinical and translational scientific research and technologies related to personalized medicine (e.g., precision medicine, pharmacogenomics/proteomics, systems biology, 'omics association analysis). *JPM* is covered in Scopus, the Science Citation Index Expanded (SCIE), PubMed, PMC, Embase, and other databases.

Editor-in-Chief

Prof. Dr. Kenneth P.H. Pritzker

Department of Laboratory Medicine and Pathobiology, Department of Surgery, University of Toronto, 6 Queens Pk Crescent W,F, Toronto, ON M5S 3H2, Canada

Author Benefits

High Visibility:

indexed within Scopus, PubMed, PMC, Embase, and other databases.

Journal Rank:

CiteScore - Q1 (Medicine (miscellaneous))

Rapid Publication:

manuscripts are peer-reviewed and a first decision is provided to authors approximately 21.5 days after submission; acceptance to publication is undertaken in 3.5 days (median values for papers published in this journal in the first half of 2025).